Filing Flows › 13F managers › Pfizer
Pfizer: 13F portfolio Q2 2026 and what copying it returned
Pfizer's 13F for the quarter ended 2026-06-30 (filed Aug 13, 2026): 17 common-share positions, $170M reported. Copying each 13F the day after it was filed returned -3.9% from May 15, 2025 to Nov 6, 2026, against +25.1% for SPY.
Copying the 13F
Each 13F bought at the close of the first trading day after it was filed and held, drifting, until the next one; value-weighted over the common-share positions with a price (85.0% of the portfolio on average); 6 filings since May 13, 2025. Price returns for the clone and SPY alike (no dividends, no costs). A 13F lists only US long positions at quarter end, reported up to 45 days later.
Largest holdings (2026-06-30)
| Ticker | Company | Weight | Value | Change in the quarter |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics | 27.6% | $46.9M | unchanged |
| CELC | Celcuity | 17.3% | $29.6M | unchanged |
| ARVN | Arvinas | 16.2% | $27.7M | unchanged |
| PYXS | Pyxis Oncology | 11.4% | $19.5M | unchanged |
| CRBU | Caribou Biosciences | 4.6% | $7.9M | unchanged |
| SPRO | Spero Therapeutics | 3.1% | $5.3M | unchanged |
| ZNTL | Zentalis Pharmaceuticals | 2.3% | $3.9M | unchanged |
| ORIC | Oric Pharmaceuticals | 2.1% | $3.6M | -92.2% |
| CRDF | Cardiff Oncology | 1.8% | $3.0M | unchanged |
| AGMB | AgomAb Therapeutics NV | 0.6% | $1.0M | unchanged |
| BOLT | Bolt Biotherapeutics | 0.1% | $134K | unchanged |
| NXTC | NextCure | 0.0% | $73K | -71.1% |
| DNA | Ginkgo Bioworks Holdings | 0.0% | $30K | unchanged |
Biggest adds
- None reported.
Biggest cuts
- QTTB exit
- ORIC -92.2%
- NXTC -71.1%
Track record
Of 10 position changes scored in 10 separate decisions, 60.0% were on the right side of SPY over the next three months (Disclosures → Smart money).
Open in Disclosures → every quarter, the clone month by month, the smart-money record
Source: SEC Form 13F-HR, filer CIK 78003. Not investment advice.